Heron Therapeutics (HRTX) Total Debt (2011 - 2026)

Heron Therapeutics (HRTX) has reported Total Debt for 15 consecutive years, with $108.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Debt fell 27.42% year-over-year to $108.7 million; the trailing twelve-month figure through Jun 2026 stood at $108.7 million (down 27.42% YoY), and the FY2025 full-year result was $107.9 million, up 331.15% from the prior year.
• Total Debt held at $108.7 million in Q2 2026 per HRTX's latest filing, from $108.3 million in the prior quarter.
• Across five years, Total Debt topped out at $149.8 million in Q2 2025 and bottomed at $24.0 million in Q3 2023.
• Historically, Total Debt has averaged $62.9 million across 4 years, with a median of $25.1 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Total Debt surged 508.13% in 2025, then fell 27.42% in 2026.
• Over 4 years, Total Debt stood at $24.3 million in 2023, then rose by 3.14% to $25.0 million in 2024, then soared by 331.15% to $107.9 million in 2025, then grew by 0.77% to $108.7 million in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $108.7 million, $108.3 million, and $107.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.